Courage. The name hits like a statement of intent, not branding. Courage Therapeutics isn’t here to chase buzzwords, they’re out to rewire how we think about obesity, eating disorders, and the neural circuits that control them. Founded in 2019 as a University of Michigan spinout by Dr. Roger Cone and Dan Housman, this team’s got decades of receptor biology baked into its bloodstream. From Newton, MA, to Ann Arbor, MI, they’re bridging science and strategy with a precision that feels less biotech startup, more moonshot built in a lab coat. When your founding scientist literally cloned the melanocortin receptors that govern body weight, you don’t speculate, you execute.
This week, Courage Therapeutics closed its seed financing, clocking in at $11M+ across a multi-tranche round led by Arsenal Bridge Ventures. The firm, anchored in Austin and co-founded by Isaac Barchas and Jim Graham, with Reid Hoffman and Dr. Clay Siegall as special partners, isn’t in the habit of guessing right; they analyze, wait, and then go all in. The first $7.8M dropped in May ’25, the final close hit in Nov ’25, and together they’re powering a company poised to move from pre-clinical promise to IND-enabling reality. Arsenal Bridge’s bet here isn’t just financial, it’s philosophical. They’re backing science that redefines obesity not as a lifestyle issue but a brain-circuit problem.
Enter CEO Giovanni Ferrara, who took the reins in June ’25 with the calm of someone who’s been through the biotech gauntlet. He built Medeor Therapeutics through late-stage trials, sat inside Novartis Venture Funds, and knows how to turn raw biology into regulated value. Co-founder & board member Dan Housman brings entrepreneurial steel and personal stakes as a parent who’s lived the challenges of anorexia and ARFID at home. And in the background, Dr. Roger Cone still drives the science from Ann Arbor, the same mind that first linked MC4R and MC3R to feeding behavior decades ago.
This round fuels 2 flagship programs. The MC4R agonist pipeline targets genetic and dietary obesity, showing synergy with GLP-1 drugs like Ozempic and Mounjaro, essentially giving them brains to go with their brawn. It’s about amplifying results, not overmedicating. The MC3R program flips focus to restrictive eating disorders like anorexia and cachexia, a frontier with no FDA-approved therapy today. Leading drug discovery is Dr. Tomi Sawyer, the chemist behind Scenesse® and Iclusig®, whose fingerprints are on some of biotech’s biggest molecular wins.
The play here isn’t hype; it’s horizon. The obesity market might be a $100B juggernaut, but Courage Therapeutics is chasing what’s next, not what’s trending. When the world realizes weight control isn’t a one-pathway problem, this company will already be standing there, data-verified, clinically ready, and proving that real courage doesn’t talk about changing the game. It just does it.
